Clinical trials found that using the Prostate Health Index (phi) test could have spared 30% of unnecessary biopsies for patients who had benign or insignificant prostate cancer. A new study looked at the impact of phi testing in a real-world clinical setting. When compared to patients who did not have phi tests, the study showed that incorporating phi into clinical practice reduced unnecessary biopsies by 9% while still detecting the same proportion of clinically-significant cancers.
Phi is a simple blood test that is nearly three times more accurate than the free/total PSA test. Dr. Catalona led the pivotal study on phi that gained its approval by the U.S. FDA.